Merck & Company (MRK) Stock Forecast & Price Target

Compare

14,142 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Moderate Buy

7 Buy

9 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$100.00

▲(23.24% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $100.00 with a high forecast of $141.00 and a low forecast of $82.00. The average price target represents a 23.24% change from the last price of $81.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"$73","142":"$142","90.25":"$90.3","107.5":"$107.5","124.75":"$124.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":141,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$141.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,90.25,107.5,124.75,142],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.64,88.97538461538461,93.31076923076924,97.64615384615385,101.98153846153846,106.31692307692308,110.65230769230769,114.98769230769231,119.32307692307693,123.65846153846154,127.99384615384616,132.32923076923078,136.6646153846154,{"y":141,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.64,85.82153846153847,87.00307692307692,88.18461538461538,89.36615384615385,90.5476923076923,91.72923076923077,92.91076923076923,94.09230769230768,95.27384615384615,96.45538461538462,97.63692307692307,98.81846153846153,{"y":100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.64,84.43692307692308,84.23384615384616,84.03076923076924,83.8276923076923,83.62461538461538,83.42153846153846,83.21846153846154,83.01538461538462,82.8123076923077,82.60923076923076,82.40615384615384,82.20307692307692,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":113.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.24,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$141.00

Average Price Target$100.00

Lowest Price Target$82.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$100→$90

Hold

10.92%

Upside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Luisa Hector

Berenberg Bank

$100→$90

Hold

10.92%

Upside

Downgraded

09/16/25

Berenberg Bank downgrades Merck & Company (MRK) to a Hold

Chris Schott

J.P. Morgan

$120

Buy

47.89%

Upside

Reiterated

09/16/25

J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)We are establishing a Dec 2026 price target of $120 (vs prior Dec 2025 PT of $120)

Veda Pharmyne

TR | OpenAI - 4o

$96→$93

Buy

14.62%

Upside

Reiterated

09/13/25

AI Generated ArticleAI Generated Article

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

09/09/25

Merck's Strategic Advantage in ADCs for ES-SCLC: A Buy Rating by Daina GrayboschWe believe that Merck (MRK, OP) / Daiichi’s (DSNKY, Not Rated) strong Ph 2 IDeate-Lung01 update for I-DXd (B7- H3-topo1i-ADC) supports accelerated approval (AA) in 2/3L extensive-stage SCLC, and consequently a significant first-to- market commercial advantage over other emerging ADCs with topo1i payloads. While we do not anticipate upside for MRK near- term from this data, we do believe that AA next year could be an important catalyst on the journey to build investor appreciation in Merck's broader oncology portfolio.

Asad Haider

Goldman Sachs

$94

Buy

15.85%

Upside

Reiterated

08/19/25

Merck & Co.'s Strategic Positioning and Market Potential Justify Buy Rating Despite ChallengesWe note these actions follow the recent company’s price-promotion initiatives since May where it is providing a free last shot of Gardasil in different age groups (free second dose to 9-14 year-old recipients in a few provinces, and free third dose in 15-45 year-old group) an effort to continue to wind down excess inventory. Our Zhifei analyst now estimates 20% ASP decline from such promotions and further revises down sales and volume projections for Gardasil in 2025E, though notes positive trends with respect to ongoing the inventory impairment. As a reminder, alongside its 2Q25 earnings, MRK again pushed out its expectations for an inﬂection in China Gardasil, noting it plans no shipments at least through the end of this year, citing elevated inventories and soft demand.

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/17/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Evan Seigerman

BMO Capital

$82

Hold

1.06%

Upside

Reiterated

08/04/25

BMO Capital Sticks to Its Hold Rating for Merck & Company (MRK)

Mohit Bansal

Wells Fargo

$97→$90

Hold

10.92%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Carter Gould

Cantor Fitzgerald

$83

Hold

2.29%

Upside

Reiterated

07/29/25

Cantor Fitzgerald Sticks to Its Hold Rating for Merck & Company (MRK)

Steve Scala

TD Cowen

$100

Hold

23.24%

Upside

Reiterated

07/28/25

Tim Anderson

Bank of America Securities

$99

Buy

22.01%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Vamil Divan

Guggenheim

$108

Buy

33.10%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung Huynh

UBS

$105

Buy

29.41%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho Peterson

Jefferies

$138→$141

Buy

73.77%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$100→$90

Hold

10.92%

Upside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Luisa Hector

Berenberg Bank

$100→$90

Hold

10.92%

Upside

Downgraded

09/16/25

Berenberg Bank downgrades Merck & Company (MRK) to a Hold

Chris Schott

J.P. Morgan

$120

Buy

47.89%

Upside

Reiterated

09/16/25

J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)We are establishing a Dec 2026 price target of $120 (vs prior Dec 2025 PT of $120)

Veda Pharmyne

TR | OpenAI - 4o

$96→$93

Buy

14.62%

Upside

Reiterated

09/13/25

AI Generated ArticleAI Generated Article

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

09/09/25

Asad Haider

Goldman Sachs

$94

Buy

15.85%

Upside

Reiterated

08/19/25

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/17/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Evan Seigerman

BMO Capital

$82

Hold

1.06%

Upside

Reiterated

08/04/25

BMO Capital Sticks to Its Hold Rating for Merck & Company (MRK)

Mohit Bansal

Wells Fargo

$97→$90

Hold

10.92%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Carter Gould

Cantor Fitzgerald

$83

Hold

2.29%

Upside

Reiterated

07/29/25

Cantor Fitzgerald Sticks to Its Hold Rating for Merck & Company (MRK)

Steve Scala

TD Cowen

$100

Hold

23.24%

Upside

Reiterated

07/28/25

Tim Anderson

Bank of America Securities

$99

Buy

22.01%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Vamil Divan

Guggenheim

$108

Buy

33.10%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung Huynh

UBS

$105

Buy

29.41%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho Peterson

Jefferies

$138→$141

Buy

73.77%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+1.53%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.53% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+2.76%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +2.76% per trade.

1 Year

Tim AndersonBank of America Securities

Success Rate

9/14 ratings generated profit

Average Return

+4.36%

reiterated a buy rating 2 months ago

Copying Tim Anderson's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +4.36% per trade.

2 Years

xxx

Success Rate

15/18 ratings generated profit

Average Return

+12.19%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +12.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 25 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 100.00.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.37 with a range of $2.32 to $2.46. The previous quarter’s EPS was $2.13. MRK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $17.02B with a range of $16.61B to $17.37B. The previous quarter’s sales results were $15.80B. MRK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 100.00.

What is MRK’s upside potential, based on the analysts’ average price target?

Merck & Company has 23.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRK a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy which is based on 7 buy ratings, 9 hold ratings and 0 sell ratings.

What is Merck & Company’s price target?

The average price target for Merck & Company is 100.00. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 23.24% Increase from the current price of $81.14.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of MRK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merck & Company (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts